Domperidone: A review of its use in diabetic gastropathy

Drugs

Volumn 56, Issue 3, 1998, Pages 429-445

  Prakash, Amitabh ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISAPRIDE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; METOCLOPRAMIDE; PROLACTIN;

AMENORRHEA; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG WITHDRAWAL; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRANSIT; HEADACHE; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MASTALGIA; META ANALYSIS; MUSCLE CRAMP; ORAL DRUG ADMINISTRATION; PROLACTIN BLOOD LEVEL; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; STOMACH DISEASE; STOMACH EMPTYING; SYMPTOM;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DOMPERIDONE; DOPAMINE ANTAGONISTS; HUMANS; STOMACH DISEASES;

EID: 0031684995     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856030-00011     Document Type: Review

References (94)

1. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994; 37 (6): 543-51
2. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985 Jan; 30: 1-9
3. Sturm A, Holtmann G, Goebell H. Treatment of patients with gastroparesis: a meta-analysis of prokinetics [ahstract]. Gastroenterology 1997 Apr; 112 Suppl.: A833
4. Patterson D, Silvers D, Kipnes M, et al. Does gastric emptying status in patients with diabetes influence the effectiveness of domperidone? [abstract]. Gastroenterology 1997 Apr: 112 Suppl.: A804
5. Horowitz M, Maddox AF, Wishart JM, et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18: 229-34
6. Mearin F, Malagelada J-R. Gustroparesis and dyspepsia in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995; 7 (8): 717-23
7. National Diabeles Data Group (U.S.). Digestive diseases and diabetes. In: Diabetes in America. 2nd ed. Bethesda: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995: 464-6
8. Koch KL. Diabetic gastropathy: a clinical overview. Patient Care 1998 Jan; Supp. 1: 1-10
9. Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med 1983; 98: 378-84
10. Drenth JPH, Engels LGJB. Diabetic gastroparesis: a critical reappraisal of new treatment strategies. Drugs 1992 Oct: 44: 537-53
11. Nilsson P-H. Diabetic gastroparesis: a review. J Diabetes Complications 1996 Mar-Apr; 10: 113-22
12. Jones KL, Horowitz M, Berry M, et al. Blood glucose concentration influences postprandial fullness in IDDM. Diabetes Care 1997; 20 (7): 1141-5
13. Schvarez E, Palmer M, Åman J, et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113: 60-6
14. Samsom M, Akkermans LMA, Jebbink RJA, et al. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut 1997; 40: 641-6
15. Hehhard GS, Samsom M, Andrews JM, et al. Hyperglycemia affects gastric electrical rhythm and nausea during intraduodenal triglyceride infusion. Dig Dis Sci 1997; 42 (3): 568-75
16. Schvarcz E, Palmer M, Ingberg CM, et al. Increased prevalence ot upper gastrointestinal symptoms in long-term type I diabetes mellitus. Diabetic Med 1996; 13: 478-81
17. Hebbard GS, Samsom M, Sun WM, et al. Hyperglycemia affects proximal gastric motor and sensory function during small intestinal triglyceride infusion. Am J Physiol 1996; 271: G814-9
18. Kendall BJ, McCallum RW. Gastroparesis and the current use of prokinetic drugs. Gastroenterologist 1993 Jun; 1: 107-14
19. Brogden RN, Carmine AA, Heel RC, et al. Domperidone: a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982 Nov; 24: 360-400
20. Corazza GR, Biagi F, Albano O, et al. Levosulpiride in functional dyspepsia: a multicentric double-blind, controlled trial. Ital J Gastroenterol 1996; 28: 317-23
21. Gatto G, Ricca T, Randazzo MA, et al. Clinical efficacy and safety of levosulpiride and domperidone in the management of chronic functional dyspepsia: a double-blind, randomized clinical trial. Curr Ther Res 1992 May; 51: 715-22
22. Halter F, Staub P, Hammer B, et al. Study with two prokinetics in functional dyspepsia and GORD: domperidone vs cisapride. J Physiol Pharmacol 1997; 48 (2): 185-92
23. 1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 1983 Apr 22; 89: 137-41
24. Takahashi T, Kurosawa S, Wiley JW, et al. Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 1991 Sep: 101: 703-10
25. Nasello AG, Gidali D, de Sá-Rocha LC, et al. Differential effects of bromopride and domperidone on cholinesterase activity in rat tissues. Life Sci 1994 Dec 9; 56: 151-6
26. Kurosawa S, Owyang C. Characterizations of dopamine receptors on gastric smooth muscle and on postsynaplic cholinergic neurons. Mechanism for the gastrokinclic action of domperidone [abstract]. Gastroenterol Jpn 1993 Aug; 28: 586
27. Sahyoun HA, Costall B, Naylor RJ. On the ability of domeridone to selectively inhibit catecholamine-induced relaxation of circular smooth muscle of guinea-pig stomach. J Pharm Pharmacol 1982 Jan; 34: 27-33
28. Sahyoun HA, Costall B, Naylor RJ. Catecholamine-induced relaxation and contraction of the lower oesophageal and pyloric sphincters of guinea-pig stomach: modification by domperidone. J Pharm Pharmacol 1982 May; 34: 318-24
29. Schuurkes JA, Van Nueten JM. Domperidone improves myogenically transmitted antroduodenal coordination by blocking dopaminergic receptor sites. Scand J Gastroenterol 1984; 96 Suppl.: 101-10
30. Laduron PM, Leysen JF. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 1979; 28: 2161-5
31. 2-test [abstract]. Dig Dis Sci 1990 Aug; 35: 1016
32. Weihrauch TR, Forster CRF, Krieglstein J. Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal mannmetry. Postgrad Med J 1979; 55 Suppl. 1: 7-10
33. Ding Y-W, Yi S-Q. Ling Q-I. Effect of domperidone and nifedipine on esophageal motility of healthy subjects and several esophageal diseases [abstract]. J Gastroenterol Hepatol 1993: 8 Suppl. 2: S206
34. Wallin L, Madsen T, Boesby S. Effect of domperidone on gastro-oesophageal function in normal human subjects. Scand J Gastroenterol 1985 Mar; 20: 150-4
35. Blackwell JN, Heading RC, Fettes MR. Effects of domperidone on lower oesophageal sphincter pressure and gastro-oesophageal reflux in patients with peptic oesophagitis. Progress with domperidone. Royal Society of Medicine International Congress and Symposium Series No. 36 (1981): 57
36. Wiley J, Owyang C. Dopaminergic modulation of rectosigmoid motilily: action of domperidone. J Pharmacol Exp Ther 1987 Aug; 242: 548-51
37. Valori RM, Kumar D, Wingate DL. Effects of different types of stress and of "prokinetic" drugs on the control of the fasting motor complex in humans. Gastroenterology 1986 Jun; 90: 1890-900
38. Weihrauch TR, Ehl W. Effect of domperidone on the motility of antrum, pylorus and duodenum in man. Scand J Gastroenterol 1981; 67 Suppl.: 195-8
39. Kyre-Brook IA, Small wood R, Johnson AG. Human antroduodenal motility, pyloric closure, and domperidone. Scand J Gastroenterol 1984; Suppl. 92: 4-7
40. Harasawa S, Miwa T. Effect of domperidone on gastric emptying in man. Naika Hokan 1981; 28 (3): 67-75
41. Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 1989 Sep; 84: 1069-75
42. Patterson D, Meldrum N, Kozarek R, et al. Long-term efficacy of domperidone in patients with diabetes and symptoms of gastroparesis [abstract no. 0490]. Diabetes 1997 May: 46 Suppl. 1: 126A
43. Shifflett J, McCallum RW. Longterm efficacy, treatment outcome and quality of life in patients receiving chronic domperidone therapy for gastroparesis [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A35
44. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997 Jun: 92: 976-80
45. Champion MC, Braaten J, Gulenchyn K. Domperidone (Motilium) compared to cisapride (Prepulsid) in the management of gastroparesis [abstract]. 10th World Congress of Gastroenterology 1994: 1122P
46. Hongo M, Okuno Y. Diabetic gastropathy in patients with autonomic neuropathy. Diabetic Med 1993; 10 Suppl. 2: 79S-81S
47. Abell TL, Camilleri M, Malagelada J-R. High prevalence of gastric electrical dysrhythmias in diabetic gastroparesis [abstract]. Gastroenterology 1985; 88: 1299
48. Koch KL, Bingaman S, Stern RM, et al. Gastric myoelectrical activity in symptomatic diabetic patients with or without gastroparesis [abstract]. Gastroenterology 1995; 108 (4 Suppl.): A630
49. Koch KL, Bingaman S, Stern RM. Withdrawal study of domperidone vs placebo in diabetic patients: effect on upper gastrointestinal symptoms and gastric myoelectrical activity [abstract]. Gastroemerology 1995: 108 (4 Suppl.): A630
50. Bernini GP, Lucarini AR, Franchi F, et al. Humoral effects of metoclopramide and domperidone in normal subjects and in hypertensive patients. J Endocrinol Invest 1988 Nov; 11: 711-6
51. Brown GM, Verhaegan H, Van Wimersma Greidanus TB, et al. Endocrine effects of domperidone: a peripheral dopamine blocking agent. Clin Endocrinol Oxf 1981 Sep; 15: 275-82
52. Coiro V, Butturini U, Gnudi A, et al. TSH and PRI. responses to domperidone and TRH in men with insulin-dependent diabetes mellitus of different duration. Horm Res 1987; 25: 206-14
53. Nerozzi D, Magnani A, Sforza V, et al. Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness. Psychiatry Res 1990 Nov; 34: 139-47
54. Nerozzi D, Magnani A, Dastoli C, et al. Prolactin responses to domperidone in chronic schizophrenia. Psychiatry Res 1992 May; 42: 159-69
55. Vigas M, Klimes I. Jurcovicová J. et al. Acute elevation of endogenous prolactin docs not influence glucose homeostasis in healthy men. Physiol Res 1993; 42: 341-5
56. Huang X et al. Study of the effect of domperidone on sex hormones among males [abstract]. J Gastroenterol Hepatol 1995; 10 Suppl. 4: 154
57. Korte P, Martin G, Luchsinger A, et al. Effects of dopaminergic antagonists on dopamine-induced cardiovascular and insulin secretion actions in hypertensive patients. Int J Clin Pharmacol Ther Toxicol 1993 Aug; 31: 404-6
58. Ensinger H, Lindner KH, Goertz A, et al. Metabolic and haemodynamic effects of dopamine plus domperidone in volunteers. Res Exp Med 1993 Aug; 193: 241-54
59. Sommers DK, Vanwyk M, Snyman JR. Effects of pergolide and domperidone on insulin and glucose plasma levels after a glucose load. S Afr J Sci 1994 Nov-Dec; 90: 601-3
60. Worth DP, Harvey JN, Brown J, et al. Domperidone treatment in man inhibits the fall in plasma renin activity induced by intravenous γ-1-glutamyl-1-dopa. Br J Clin Pharmacol 1986 May; 21: 497-502
61. MacDonald TM. Metoclopramide, domperidone and dopamine in man: actions and interactions. Eur J Clin Pharmacol 1991 Mar; 40: 225-30
62. Masci E, Caldara R, Testoni PA, et al. Lack of effect of domperidone on gastrin release: evidence for a peripheral activity of the drug. Br J Clin Pharmacol 1984 May; 17: 588-90
63. Chiodcra P, Volpi R, Delsignore R, et al. Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man. Br J Clin Pharmacol 1986 Oct; 22: 479-82
64. Chiodera P, Coiro V. Lack of effect of bromocriptine and domperidone on arginine-vasopressin response to insulin-induced hypoglyccmia in normal men. Psychoneuroendocrinology 1987; 12: 225-30
65. Luchsinger A, Grilli M, Velasco M. Metoclopramide and domperidone block the antihypertensive effect of bromocriptine in hypertensive patients. Am J Ther 1998; 5: 81-8
66. Allen MJ, Ang VTY, Bennett ED. Domperidone, a DA2-specific dopamine antagonist, has no effect on the renal or haemodynamic response to atrial natriuretic peptide in man. Clin Sci 1988 Dec; 75: 569-75
67. Heykants J, Hendriks R, Meuldermans W, et al. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981; 6. 61-70
68. Reynolds JC, Putnam PE. Prokinetic agents. Gastroenterol Clin North Am 1992: 21 (3): 567-96
69. Raia JJ, Barone JA, Byerly WG, et al. Determination of steadystale dose proportionality of domperidone in healthy volunteers [ahstracl]. Pharmacotherapy 1990; 10(3): 253
70. Meuldermans W, Hurkmans R, Swysen E, et al. On the pharmacokinetics of domperidone in animals and man. III. Comparative study on the secretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 1981; 6: 49-60
71. Michiels M, Hendriks R, Heykants J. On the pharmacokinetics of domperidone in animals and man. II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur J Drug Metab Pharmacokinet 1981; 6: 37-48
72. Donaldson KM, Blood P, Peters GR, et al. An evaluation of some cardiovascular effects of pramipexole in healthy volunteers and their antagonism by domperidone [abstract]. Br J Clin Pharmacol 1996; 42: 660P-1P
73. Garg SK, Dhaneria SP, Saha N, et al. Effect of domperidone on acctyl salicylic acid pharmacokinetics in Indian healthy males [abstract]. Can J Physiol Pharmacol 1994: 72 Suppl. 1: 308
74. 2-receptor antagonist. Br J Clin Pharmacol 1991; 32: 483-8
75. Patterson D, Silvers D, Kipnes M, et al. Does gastric emptying status in patienls with diabetes influence the effectiveness of domperidone? Janssen Pharmaceutica (Titusville). May 1998 (Data on file)
76. Braun AP. Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients. Adv Ther 1989 Mar-Apr; 6: 51-62
77. Patterson D, Koch K, Abell T, et al. A multi-center placebo-controlled study of domperidone in diabetic gastroparesis [abstract]. Gastroenterology 1993 Apr; 104 Suppl.: A564
78. Patterson D, Robin TN, Rothstein D, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of symptomatic diabetic gastroparesis [abstract]. Gastroenterology 1994 Apr; 106 Suppl.: A554
79. J&J motilium amended NDA filing planned by year-end; ulcerative colitis therapy ridogrel is in phase III; HIV therapy loviride development discontinued. FDC Rep Pink Sheet 1997 Sept 1: 17
80. Rashed H, Abell TL, Cardoso S, et al. Autonomic function testing correlates with response to domperidone therapy in patients with diabetes mellitus and the symptoms of gastroparesis [abstract no. 0599]. Diabetes 1997 May; 46 Suppl. 1: 155A
81. Patterson DJ, Botoman VA, Kozarek RA, et al. Domperidone is effective long-term treatment for diabetic gastroparesis [abstract]. Gastroenterology 1991 May; 100 Suppl.: A137
82. Bingaman S, Koch K. Long-term domperidone treatment for symptoms of gastroparesis in diabetic patients [abstract no. 1204]. Diabetes 1997 May; 46 Suppl. 1: 315A
83. Kozarek R. Domperidone for symptomatic management of diabetic gastroparesis in metoclopramide treatment failures. Adv Ther 1990 Mar-Apr; 7: 61-8
84. Miller M, Patterson D. Natural history of diabetic gastroparesis treated with cisapride or domperidone [abstract]. Am J Gastroenterol 1991 Sep; 86: 1316
85. Lehmann KA, Patterson DJ. Does combination prokinetic therapy benefit patients with refractory diabetic gastroparesis [abstract]? Gastroenterology 1995; 108 (4 Suppl.): A636
86. Quigley E, Kline LN, Murray M, et al. Domperidone improves health-related quality of life in patients with gastrointestinal symptoms associated with diabetic gastroparesis [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A36
87. Quigley E, Leidy NK, Murray M, et al. Domperidone improves health-related quality of life in patients with gastrointestinal symptoms associated with diabetic gastroparesis. Janssen Pharmaceutica (Titusville). May 1998 (Data on file)
88. Abell TL, Rashed H, Cutts T, et al. Autonomic function is a determinant of quality of life improvement in response to domperidone therapy [abstract no. 1445]. Diabetes 1997 May; 46 Suppl. 1: 381A
89. Silvers D, Kipnes M, Broadstone V, et al. Domperidone significantly improves gastrointestinal symptoms associated with diabetic gastroparesis [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: 826
90. Bonuccelli U, Nocchiero A, Napolitano A, et al. Domperidone-induced acute dystonia and polycystic ovary syndrome. Mov Disord 1991; 6(1); 79-81
91. Stern WR. Summary of the 34th Meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee. March 15 and 16, 1989 (omeprazole and domperidone). Am J Gastroenterol 1989 Nov; 84: 1351-5
92. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone [short report]. BMJ 1984; 289: 1579
93. British National Formulary. No. 35. London: The Pharmaceutical Press, 1998 Mar
94. Horowitz M, Fraser RJ. Gastroparesis: diagnosis and management. Scand J Gastroenterol 1995; 213 Suppl.: 7-16